The Safety Standard: Evaluating Cryopreserved Equine UC Allografts
- Oct 1, 2025
- 2 min read
Updated: Apr 23
This summary highlights the robust safety profile of a cryopreserved equine umbilical cord allograft, as demonstrated through three comprehensive in vivo studies published in “Cryopreserved equine umbilical cord tissue allograft characterization and biocompatibility in vivo in musculoskeletal tissues: a controlled study.” BMC Medicine, 2025.1
Study Overview
Three in vivo studies evaluated safety and biocompatibility of cryopreserved equine umbilical cord (UC) allograft.
Focus on musculoskeletal (MSK) tissues: joints, ligaments, and tendons.
Assessed in clinically normal horses, horses with MSK disease, and through histopathology.
1. Controlled Study in Normal Horses
Design:
Randomized, masked, crossover study with 8 horses.
Intervention:
UC allograft injected into joints and ligaments; saline as control.
Findings:
No lameness, pain, or swelling post-injection.
Transient synovitis resolved by Day 5–10.
No systemic inflammation (normal SAA levels).
Increased anti-inflammatory cytokines (IL-1ra, IL-10).
IL-1ra/IL-1 ratio improved >4-fold.
2. Case Series in Diseased Horses
Findings:
No adverse events or systemic inflammation
Improved lameness and pain scores.
Synovial fluid returned to baseline by Day 3.
Increased anti-inflammatory cytokines.
No tissue damage on imaging.
Subjects:
3 horses with osteoarthritis, desmitis, and tendonitis.
Intervention: Single UC injection into affected tissues.
3. Controlled Pathologic Study
Subjects:
2 horses received multiple UC injections.
Assessment:
Histologic evaluation of joints, ligaments, and lymph nodes.
Findings:
No immune reaction or tissue damage.
Mild inflammation only at needle tracts.
No foreign body response or lymph node activation
Conclusion
UC allograft demonstrated excellent local and systemic safety.
No adverse immune or inflammatory responses observed.
Consistent anti-inflammatory effects and histologic biocompatibility.
Supports use as a safe injectable biologic for MSK tissue supplementation.
Ready to Explore equicenta™ CTM for Your Practice?
The peer-reviewed data speaks for itself: consistent protein profiles, proven biocompatibility, and measurable clinical outcomes in musculoskeletal conditions.
Comments